Trial Profile
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ENLIGHTEN
- Sponsors Bristol-Myers Squibb; Celgene Corporation
- 02 Mar 2024 Results of an ad hoc interim analysis (n= 185) assessing patient-reported outcomes (PROs) after 1 y of ozanimod, presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 02 Mar 2024 Interim Results (n=116) assessing changes in cognitive functioning over 1 year presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
- 29 Feb 2024 According to a Bristol-Myers Squibb Media Release, interim data will be presented at the 9th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida taking place February 29 to March 2.